TrialCurrent neuropharmacology2026

Vortioxetine for the Treatment of Depression in Patients with Parkinson's Disease: A 16-week Pilot, Prospective, Open-label Safety Study.

Fabrizio Stocchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.